Consun Pharmaceutical Group Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Consun Pharmaceutical Group kazanç ve gelirin sırasıyla yıllık 14.7% ve 13.3% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 14.1% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 23.8% olacağı tahmin edilmektedir.

Anahtar bilgiler

14.7%

Kazanç büyüme oranı

14.1%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	11.0%
Gelir büyüme oranı	13.3%
Gelecekteki özkaynak getirisi	23.8%
Analist kapsamı	Low
Son güncelleme	22 Nov 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

These 4 Measures Indicate That Consun Pharmaceutical Group (HKG:1681) Is Using Debt Safely

Nov 27

Consun Pharmaceutical Group Limited's (HKG:1681) Shares Leap 32% Yet They're Still Not Telling The Full Story

Oct 02

Here's Why Consun Pharmaceutical Group (HKG:1681) Has Caught The Eye Of Investors

Sep 26

Consun Pharmaceutical Group (HKG:1681) Has Announced That It Will Be Increasing Its Dividend To HK$0.10

Aug 26

Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Rather Sparingly

Apr 21

Does It Make Sense To Buy Consun Pharmaceutical Group Limited (HKG:1681) For Its Yield?

Mar 17

Here's Why Consun Pharmaceutical Group's (HKG:1681) Statutory Earnings Are Arguably Too Conservative

Feb 19

How Much Did Consun Pharmaceutical Group's(HKG:1681) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 29

Could The Consun Pharmaceutical Group Limited (HKG:1681) Ownership Structure Tell Us Something Useful?

Jan 08

Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Quite Sensibly

Dec 18

Should Consun Pharmaceutical Group Limited (HKG:1681) Be Part Of Your Income Portfolio?

Nov 18

Kazanç ve Gelir Büyüme Tahminleri

SEHK:1681 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	3,832	1,213	N/A	1,249	2
12/31/2025	3,299	1,019	699	1,032	3
12/31/2024	2,929	896	657	905	3
6/30/2024	2,739	836	833	915	N/A
3/31/2024	2,665	810	800	867	N/A
12/31/2023	2,590	785	766	819	N/A
9/30/2023	2,528	759	797	844	N/A
6/30/2023	2,466	734	828	869	N/A
3/31/2023	2,403	708	862	908	N/A
12/31/2022	2,340	683	896	948	N/A
9/30/2022	2,246	660	836	906	N/A
6/30/2022	2,152	636	776	865	N/A
3/31/2022	2,098	613	701	795	N/A
12/31/2021	2,045	590	627	726	N/A
9/30/2021	1,959	565	655	731	N/A
6/30/2021	1,874	541	683	737	N/A
3/31/2021	1,813	520	748	802	N/A
12/31/2020	1,753	499	813	867	N/A
9/30/2020	1,653	269	639	717	N/A
6/30/2020	1,553	39	465	567	N/A
3/31/2020	1,641	60	334	475	N/A
12/31/2019	1,728	80	203	383	N/A
9/30/2019	1,822	288	231	442	N/A
6/30/2019	1,916	496	259	501	N/A
3/31/2019	1,880	481	410	628	N/A
12/31/2018	1,844	465	561	754	N/A
9/30/2018	1,802	448	519	662	N/A
6/30/2018	1,760	430	476	570	N/A
3/31/2018	1,710	413	N/A	411	N/A
12/31/2017	1,660	396	N/A	252	N/A
9/30/2017	1,601	372	N/A	323	N/A
6/30/2017	1,541	347	N/A	393	N/A
3/31/2017	1,382	327	N/A	421	N/A
12/31/2016	1,223	308	N/A	449	N/A
9/30/2016	1,060	291	N/A	362	N/A
6/30/2016	896	274	N/A	275	N/A
3/31/2016	863	262	N/A	230	N/A
12/31/2015	831	250	N/A	184	N/A
9/30/2015	814	246	N/A	180	N/A
6/30/2015	798	242	N/A	175	N/A
3/31/2015	764	226	N/A	235	N/A
12/31/2014	731	211	N/A	295	N/A
9/30/2014	697	198	N/A	285	N/A
6/30/2014	664	185	N/A	275	N/A
3/31/2014	618	169	N/A	219	N/A
12/31/2013	572	153	N/A	164	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 1681 'nin tahmini kazanç büyümesi (yıllık 14.7% ) tasarruf oranının ( 2.3% ) üzerindedir.

Kazançlar ve Piyasa: 1681 şirketinin kazançlarının (yıllık 14.7% ) Hong Kong pazarından (yıllık 11.5% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 1681 şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: 1681 şirketinin gelirinin (yıllık 13.3% ) Hong Kong pazarından (yıllık 7.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 1681 şirketinin gelirinin (yıllık 13.3% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 1681 'in Özsermaye Getirisi'nin 3 yıl içinde yüksek olması tahmin ediliyor ( 23.8 %)

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/24 04:14
Gün Sonu Hisse Fiyatı	2024/12/24 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Consun Pharmaceutical Group Limited 8 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Fangqi Dai	China Merchants Securities (HK) Co., Ltd
null null	CMB International Securities Limited
Trina Chen	Credit Suisse

Consun Pharmaceutical Group Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

These 4 Measures Indicate That Consun Pharmaceutical Group (HKG:1681) Is Using Debt Safely

Consun Pharmaceutical Group Limited's (HKG:1681) Shares Leap 32% Yet They're Still Not Telling The Full Story

First half 2024 earnings released: EPS: CN¥0.50 (vs CN¥0.44 in 1H 2023)

Investor sentiment improves as stock rises 15%

Here's Why Consun Pharmaceutical Group (HKG:1681) Has Caught The Eye Of Investors

CEO & Executive Chairman recently bought HK$5.4m worth of stock

First half dividend of HK$0.30 announced

Consun Pharmaceutical Group Limited Announces Executive Changes

Consun Pharmaceutical Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on 20 September 2024

Consun Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024

Consun Pharmaceutical Group Limited Receives Notice of Approval for Clinical Trial of Drug for SK-08 Tablet

CEO & Executive Chairman recently bought HK$7.7m worth of stock

Consun Pharmaceutical Group Limited Announces Board and Committee Changes

Chief Scientist & Executive Director recently sold HK$8.4m worth of stock

Consun Pharmaceutical Group (HKG:1681) Has A Rock Solid Balance Sheet

New minor risk - Shareholder dilution

Consun Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2023

Insider recently sold HK$62m worth of stock

Consun Pharmaceutical Group Limited Announces Special Dividend, Payable on 21 June 2024

Consun Pharmaceutical Group's (HKG:1681) Dividend Will Be CN¥0.30

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consun Pharmaceutical Group Limited, Annual General Meeting, May 31, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consun Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 21 June 2024

Consun Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Consun Pharmaceutical Group Limited Announces Management Changes

First half 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.37 in 1H 2022)

Upcoming dividend of HK$0.15 per share at 6.2% yield

First half 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.37 in 1H 2022)

Consun Pharmaceutical Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2023, Payable on 20 September 2023

Consun Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 24, 2023

Consun Pharmaceutical Group (HKG:1681) Is Increasing Its Dividend To CN¥0.30

Consun Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2022

Upcoming dividend of HK$0.30 per share at 6.0% yield

Consun Pharmaceutical Group (HKG:1681) Has A Rock Solid Balance Sheet

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: Revenues exceed analyst expectations

Investor sentiment improved over the past week

Less than half of directors are independent

First half 2022 earnings released: EPS: CN¥0.37 (vs CN¥0.31 in 1H 2021)

Consun Pharmaceutical Group Limited to Report First Half, 2022 Results on Aug 26, 2022

Investor sentiment deteriorated over the past week

Consun Pharmaceutical Group Limited, A Wholly-Owned Subsidiary of Consun Pharmaceutical (Horgos) Co., Ltd Holds A Trial Production Ceremony in Plant No. 8, Area A05, Horgos Comprehensive Bonded Zone, Yili Kazakh

Consun Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2021

Upcoming dividend of HK$0.20 per share

Full year 2021 earnings released: EPS: CN¥0.74 (vs CN¥0.61 in FY 2020)

Consun Pharmaceutical Group (HKG:1681) Will Pay A Dividend Of HK$0.20

Consun Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2021, Payable on or About 17 June 2022

Less than half of directors are independent

Consun Pharmaceutical Group (HKG:1681) Has Announced A Dividend Of HK$0.20

Investor sentiment improved over the past week

Upcoming dividend of HK$0.10 per share

Consun Pharmaceutical Group (HKG:1681) Has Announced That It Will Be Increasing Its Dividend To HK$0.10

First half 2021 earnings released: EPS CN¥0.31 (vs CN¥0.25 in 1H 2020)

Investor sentiment improved over the past week

Chairman of the Board Yubao An has left the company

Upcoming dividend of HK$0.20 per share

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.61 (vs CN¥0.094 in FY 2019)

Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Rather Sparingly

Full year 2020 earnings released: EPS CN¥0.61 (vs CN¥0.094 in FY 2019)

Investor sentiment improved over the past week

Does It Make Sense To Buy Consun Pharmaceutical Group Limited (HKG:1681) For Its Yield?

Consun Pharmaceutical Group Limited to Report Fiscal Year 2020 Results on Mar 23, 2021

Here's Why Consun Pharmaceutical Group's (HKG:1681) Statutory Earnings Are Arguably Too Conservative

How Much Did Consun Pharmaceutical Group's(HKG:1681) Shareholders Earn From Share Price Movements Over The Last Three Years?

New 90-day high: HK$3.40

Could The Consun Pharmaceutical Group Limited (HKG:1681) Ownership Structure Tell Us Something Useful?

Consun Pharmaceutical Group (HKG:1681) Seems To Use Debt Quite Sensibly

Should Consun Pharmaceutical Group Limited (HKG:1681) Be Part Of Your Income Portfolio?

First half earnings released

First half earnings released

New 90-day low - HK$3.02

Kazanç ve Gelir Büyüme Tahminleri